SCHEMBL17899877

SCHEMBL17899877

CC(C)(Sc1ccc2cnsc2c1-c1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 19/20 1.00
PPARA Q07869 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17899905 0.87 SLC22A12 (0.81) SLC22A12
SCHEMBL17899909 0.87 SLC22A12 (0.78) SLC22A12
SCHEMBL19435472 0.87 SLC22A12 (0.77) SLC22A12PPARA
SCHEMBL17899930 0.86 SLC22A12 (1.00) SLC22A12PPARA
SCHEMBL17899888 0.86 SLC22A12 (0.76) SLC22A12PPARA
SCHEMBL17899908 0.84 SLC22A12 (0.80) SLC22A12
SCHEMBL19547900 0.84 SLC22A12 (0.72) SLC22A12
SCHEMBL29441759 0.83 SLC22A12 (0.78) SLC22A12PPARA
SCHEMBL17899920 0.83 SLC22A12 (0.78) SLC22A12PPARA
SCHEMBL17899848 0.83 SLC22A12 (1.00) SLC22A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11278528-B2 Activator of peroxisome proliferator-activated receptor NIPPON CHEMIPHAR CO., LTD. (JP) 2022-03-22 US claimed
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP claimed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN claimed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US claimed
US-11278528-B2 Activator of peroxisome proliferator-activated receptor NIPPON CHEMIPHAR CO., LTD. (JP) 2022-03-22 US disclosed
US-11278528-B2 Activator of peroxisome proliferator-activated receptor NIPPON CHEMIPHAR CO., LTD. (JP) 2022-03-22 US disclosed
EP-3241822-B1 URAT1 INHIBITOR NIPPON CHEMIPHAR CO (JP) 2021-03-24 EP disclosed
EP-3705120-A1 ACTIVATOR FOR PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Nippon Chemiphar Co., Ltd. (JP) 2020-09-09 EP disclosed
US-20200268719-A1 ACTIVATOR OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR NIPPON CHEMIPHAR CO., LTD. (JP) 2020-08-27 US disclosed
US-20200268719-A1 ACTIVATOR OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR NIPPON CHEMIPHAR CO., LTD. (JP) 2020-08-27 US disclosed
CN-107108478-B URAT1 inhibitors 日本化学药品株式会社 2020-04-24 CN disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
US-10173990-B2 URAT1 inhibitor NIPPON CHEMIPHAR CO., LTD. (JP) 2019-01-08 US disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP disclosed
EP-3241822-A1 URAT1 INHIBITOR Nippon Chemiphar Co., Ltd. (JP) 2017-11-08 EP disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
US-20170290795-A1 URAT1 INHIBITOR J-PHARMA CO., LTD. (JP) 2017-10-12 US disclosed
WO-2016108282-A1 URAT1 INHIBITOR 日本ケミファ株式会社 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200268719-A1 ACTIVATOR OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR PPARA, PPARG, PPARD SLC22A12 2004/4885PPARA 1/4885
US-11278528-B2 Activator of peroxisome proliferator-activated receptor PPARA, PPARG, PPARD SLC22A12 2004/4885PPARA 1/4885
US-20170290795-A1 URAT1 INHIBITOR SLC10A1, XDH, URB2 SLC22A12 512/4885PPARA 563/4885
US-10173990-B2 URAT1 inhibitor SLC10A1, XDH, URB2 SLC22A12 500/4885PPARA 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.